BeyondSpring Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology cancer therapies. The company is headquartered in New York, New York. Show more

100 CAMPUS DRIVE, FLORHAM PARK, NJ, UNITED STATES, 07932, Florham Park, NJ, 07932, USA

https://beyondspringpharma.com

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

25.42M

52 Wk Range

$0.57 - $2.44

Previous Close

$0.62

Open

$0.63

Volume

26,911

Day Range

$0.60 - $0.65

Enterprise Value

19.65M

Cash

2.697M

Avg Qtr Burn

-3.831M

Insider Ownership

17.40%

Institutional Own.

14.80%

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Plinabulin Details Cancer, Chemotherapy-induced neutropenia	NDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Plinabulin + Docetaxel Details Non-small cell lung carcinoma (Non-squamous EGFR WT NSCLC)	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Plinabulin + PD-1 inhibitor + Etoposide/Platinum (EP) Details Cancer, Lung cancer, extensive-stage small-cell lung cancer (ES-SCLC)	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Plinabulin + Pembrolizumab + Docetaxel Details 2L/3L non-small cell lung cancer (NSCLC) after disease progression on 1L PD-1/L1 inhibitors +/- chemotherapy	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ST-01156 (RBM39 Degrader) Details Ewing Sarcoma And Other RBM39-Dependent Cancers	Phase 1a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.